Organic compounds -- part of the class 532-570 series – Organic compounds – Oxygen containing
Reexamination Certificate
2007-03-05
2009-10-13
Davis, Brian J (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Oxygen containing
C568S807000, C568S809000, C564S052000, C564S158000, C564S170000, C564S175000, C564S179000, C564S367000, C564S384000, C514S598000, C514S616000, C514S622000, C514S649000, C514S650000, C514S655000, C514S685000, C514S734000
Reexamination Certificate
active
07601876
ABSTRACT:
Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.
REFERENCES:
Database CAPLUS on STN, Acc. No. 1994:548935, Goodman et al. Brain Research (1994), 654(1), p. 171-176 (abstract).
Axelrad et al., “Acceleration of amyloidosis by syngeneic spleen cells from normal donors”, Am. J. Path. 78:277-284 (1975).
Axelrad et al., “Further characterization of amyloid-enhancing factor”, Lab. Invest. 47:139-146 (1982).
Benditt et al., “Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein”, Procl. Nat. Acad. Sci. USA 76:4092-4096 (1979).
Benditt, E.P. And Eriksen, N., “Amyloid protein SAA is associated with high density lipoprotein from human serum”, Procl. Nat. Acad. Sci. USA 74:4025-4028 (1977).
Cohen A.S., and Connors L.H., “The pathogenesis and biochemistry of amyloidosis”, J. Path. 151:1-10 (1987).
David et al., “Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study”, Clin. Exp. Rheum. 11:85-90 (1993).
Ein et al., “Amino acid sequence of an amyloid fibril protein of unknown origin”, J. Biol. Chem. 247:5653-5655 (1972).
Eriksen et al, “Mouse amyloid protein AA: Homology with nonimmunoglobulin protein of human and monkey amyloid substance”, Procl. Natl. Acad. Sci. 73:964-967 (1976).
Filipowicz-Sosnowska et al., “The amyloidosis of juvenile rheumatoid arthritis. Comparative studies in Polish and American children”, Arth. Rheum. 21:699-703 (1978).
Gorevic et al., “The amino acid sequence of duck amyloid A (AA) protein”, J. Immunol . 118:1113-1118 (1977).
Hazenberg B.P.C. and Van Rijswijk M.H., “Clinical and therapeutic aspects of AA amyloidosis”. Baillere's Clinical Rheumatology, 8:661-690 (1994).
Hoffman J.S. and Benditt, E.P., “Changes in high density lipoprotein content following endotoxin administration in the mouse . . . ”, J. Biol. Chem. 257:10510-10517 (1982).
Hoffman J.S. And Benditt, E.P., “Secretion of serum amyloid protein and assembly of serum amyloid protein-rich high density . . . ”, J. Biol. Chem. 257:10518-10522 (1982).
Hoffman et al., “Murine tissue amyloid protein AA: NH2-terminal sequence identity with only one of two serum amyloid protein . . . ”, J. Exp. Med. 159:641-646 (1984).
Husby et al., “Nomenclature of Amyloid and Amyloidosis”, Bull. WHO 71 (1):105-108 (1993).
Janigan D.T. and Druet R.L., “Experimental amyloidosis. Role of antigenicity and rapid induction”, Am. J. Path. 48:1013-1024 (1966).
Kindy, M.S. and De Beer, F., “A Mouse Model for Serum Amyloid A Amyloidosis”, Methods in Enzymology 309:701-716 (1999).
Kisilevsky et al., “The role of inflammatory cells in the pathogenesis of amyloidosis”, Lab. Invest. 37:544-553 (1977).
Kisilevsky, R., “From arthritis to Alzheimer's disease: current concepts on the pathogenesis of amyloidosis”, Can. J. Physiol. Pharmacol. 65:1805-1815 (1987).
Kisilevsky et al, “Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease”, Nature Medicine 1:143-148 (1995).
Kisilevsky et al., “Are elevated serum amyloid A levels and amyloid enhancing factor sufficient to induce AA amyloid depostion?”, Appl. Path. 2:308-315 (1984).
Marhaug et al., “Characterization of amyloid related protein SAA complexed with serum lipoproteins (apoSAA)”, Clin. Exp. Immunol. 50:382-389 (1982).
McAdam, K.P., and Sipe, J.D., “Murine model for human secondary amyloidoses: genetic variability of the acute-phase . . . ”, J. Exp. Med. 144:1121-1127 (1976).
McAdam et al., “Changes in human serum amyloid-A and C-reactive protein after etiocholanolene-induced inflammation”, J. Clin. Invest. 61:390-394 (1978).
Murray et al., “Synucleinopathies: A molecular and pathological review”, Clinical Neuroscience Research 1:445-455 (2001).
Sipe J.D., “Induction of the acute-phase serum protein SAA requires both RNA and protein synthesis”, Br. J. Exp. Path. 59:305-310 (1978).
Sipe et al., “Conformational flexibility of the serum amyloid precursor SAA”, Br. J. Exp. Path. 57:582-592 (1976).
Sipe et al., “Isolation and structural properties of murine SAA: the acute phase serum precursor of amyloid AA”, Immunol. Comm. 6:1-12 (1977).
Skogen et al., “A high molecular weight serum protein is the carrier for amyloid-related protein SAA”, Scand. J. Immunol. 6:1363-1368 (1977).
Skogen et al., “High-density lipoprotein as carrier for amyloid-related protein SAA in rabit serum”, Scand. J. lmmunol. 10:39-45 (1979).
Sletten et al, “The complete amino acid sequence of an amyloid fibril protein AA of unusual size (64 residues)”, Biochem. Biophys. Res. Comm. 69:19-25 (1976).
Waalen et al, “The primary structure of amyloid fibril protein AA in endotoxin-induced amyloidoses of the mink”, Eur. J. Biochem. 104:407-412 (1980).
Westermark et al., “Bovine amyloid protein AA: isolation and amino acid sequence analysis”, Comp. Biochem. Physiol. Comp. Biochem. 85:609-614 (1986).
Castillo Gerardo M.
Coffen David L.
Coffen, legal representative Charlotte
Lake Thomas P.
Larsen David S.
Davis Brian J
Eagen Rebecca
Proteotech Inc.
LandOfFree
Compounds, compositions and methods for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions and methods for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions and methods for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4057408